肿瘤细胞治疗研究
ALL SOURCES
Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strateg
然而，约30%的患者对基于venetoclax的联合方案无应答，且大多数初始应答者最终会复发。
TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions.
当前治疗方案对 TP53 突变型急性髓系白血病（AML）的获益有限，完全缓解率为 13% 至 46%，中位总生存期仅 6.1-6.5 个月。
Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.
ROR1在多种白血病和淋巴瘤中呈现出异质性的肿瘤细胞表达谱，使其成为一个需要不同患者筛选策略才能开发新型治疗模式的肿瘤靶点。
Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma.
继发性恶性肿瘤在 CAR-T 疗法后似乎更为常见。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
